Lung function trajectories in patients with idiopathic pulmonary fibrosis

被引:7
|
作者
Neely, Megan L. [1 ,2 ]
Hellkamp, Anne S. [1 ,2 ]
Bender, Shaun [3 ]
Todd, Jamie L. [1 ,2 ]
Liesching, Timothy [4 ]
Luckhardt, Tracy R. [5 ]
Oldham, Justin M. [6 ]
Raj, Rishi [7 ]
White, Eric S. [3 ]
Palmer, Scott M. [1 ,2 ]
机构
[1] Duke Clin Res Inst, Durham, NC 27701 USA
[2] Duke Univ, Med Ctr, Durham, NC 27710 USA
[3] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[4] Lahey Hosp & Med Ctr, Burlington, MA USA
[5] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA
[6] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI USA
[7] Stanford Univ, Sch Med, Stanford, CA USA
关键词
Interstitial lung disease; Lung function testing; Forced vital capacity; FORCED VITAL CAPACITY; CLINICAL-COURSE; INTERSTITIAL PNEUMONIA; SURVIVAL; PROGRESSION; MORTALITY; PIRFENIDONE; SPIROMETRY; NINTEDANIB; EFFICACY;
D O I
10.1186/s12931-023-02503-5
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterised by decline in lung function. We evaluated trajectories of forced vital capacity (FVC) and diffusing capacity (DLco) in a cohort of patients with IPF.Methods Patients with IPF that was diagnosed or confirmed at the enrolling centre in the previous 6 months were enrolled into the IPF-PRO Registry between June 2014 and October 2018. Patients were followed prospectively, with lung function data collected as part of routine clinical care. Mean trajectories of FVC and DLco % predicted in all patients and in subgroups by characteristics assessed at enrolment were estimated using a joint model that accounted for factors such as disease severity and visit patterns. Results Of 1002 patients in the registry, 941 had = 1 FVC and/or DLco measurement after enrolment. The median (Q1, Q3) follow-up period was 35.1 (18.9, 47.2) months. Overall, mean estimated declines in FVC and DLco % predicted were 2.8% and 2.9% per year, respectively. There was no evidence that the mean trajectories of FVC or DLco had a non-linear relationship with time at the population level. Patients who were male, white, had a family history of ILD, were using oxygen, or had prior/current use of antifibrotic therapy at enrolment had greater rates of decline in FVC % predicted. Patients who were male or white had greater rates of decline in DLco % predicted.Conclusions Data from the IPF-PRO Registry suggest a constant rate of decline in lung function over a prolonged period, supporting the inexorably progressive nature of IPF. A graphical abstract summarising the data in this manuscript is available at: https://www.usscicomms.com/respiratory/IPF-PRORegistry_LungFunctionTrajectories.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment
    Nathan, Steven D.
    Costabel, Ulrich
    Albera, Carlo
    Behr, Juergen
    Wuyts, Wim A.
    Kirchgaessler, Klaus-Uwe
    Stauffer, John L.
    Morgenthien, Elizabeth
    Chou, Willis
    Limb, Susan L.
    Noble, Paul W.
    RESPIRATORY MEDICINE, 2019, 153 : 44 - 51
  • [22] Fibrinolytic system related to pulmonary arterial pressure and lung function of patients with idiopathic pulmonary fibrosis
    Ban, Chengjun
    Wang, Tongde
    Zhang, Shu
    Xin, Ping
    Liang, Lirong
    Wang, Chen
    Dai, Huaping
    CLINICAL RESPIRATORY JOURNAL, 2017, 11 (05): : 640 - 647
  • [23] A Disease Progression Model of Longitudinal Lung Function Decline in Idiopathic Pulmonary Lung Fibrosis Patients
    Bi, Youwei
    Paterniti, Miya O.
    Karimi-Shah, Banu A.
    Chowdhury, Badrul A.
    Wang, Yaning
    Rekic, Dinko
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S47 - S48
  • [24] Air Pollution Exposure Is Associated With Lower Lung Function, but Not Changes in Lung Function, in Patients With Idiopathic Pulmonary Fibrosis
    Johannson, Kerri A.
    Vittinghoff, Eric
    Morisset, Julie
    Wolters, Paul J.
    Noth, Elizabeth M.
    Balmes, John R.
    Collard, Harold R.
    CHEST, 2018, 154 (01) : 119 - 125
  • [25] Severity and Extent of Pulmonary Fibrosis on CT in Idiopathic Pulmonary Fibrosis Patients Correlates With Lung Function and Quantitative CT Features
    Ko, H.
    Choi, J.
    Chung, W.
    Chae, K.
    Lee, C.
    Choi, S.
    Lee, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [26] Association Between Changes In Quantitative CT Lung Fibrosis Score And Pulmonary Function Tests In Patients With Idiopathic Pulmonary Fibrosis
    Kim, H. J. G.
    Brown, M. S.
    Gjertson, D.
    Lu, P.
    Coy, H.
    Goldin, J. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [27] Alterations to the Lung Microbiome in Idiopathic Pulmonary Fibrosis Patients
    Tong, Xunliang
    Su, Fei
    Xu, Xiaomao
    Xu, Hongtao
    Yang, Ting
    Xu, Qixia
    Dai, Huaping
    Huang, Kewu
    Zou, Lihui
    Zhang, Wenna
    Pei, Surui
    Xiao, Fei
    Li, Yanming
    Wang, Chen
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2019, 9
  • [28] Idiopathic pulmonary fibrosis in hospitalized patients with lung cancer
    Shi, Yujie
    Chen, Ruxuan
    Huang, Hui
    Wang, Mengzhao
    Xu, Zuojun
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [29] LUNG-CANCER IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    NAGAI, A
    CHIYOTANI, A
    NAKADATE, T
    KONNO, K
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 167 (03): : 231 - 237
  • [30] Impulse oscillometry compared to standard lung function testing in patients with idiopathic pulmonary fibrosis
    Flensborg, Emil Lind
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52